Business Wire

PHILIP-MORRIS-INTER

Share
Philip Morris International: New Study Shows Decline of Total Illicit Cigarette Consumption in the European Union in 2019 Despite Continued Increase in Counterfeiting

Philip Morris International Inc. (PMI) (NYSE: PMI) reiterated today the need for collaborative efforts against illicit trade to continue, as a new report produced by KPMG underlined the changing nature of the problem in the European Union (EU).

The independent KPMG annual study , commissioned by PMI, found that in 2019, the consumption of illicit cigarettes—which consist of contraband, counterfeit, and illicit whites—continued to decline in the EU, reaching an all-time low since the study first took place in 2006. In total, 38.9 billion illicit cigarettes were consumed, representing 7.9 percent of total cigarette consumption, a 0.7 percentage point reduction compared to the previous year.

Despite the overall decline of illicit cigarette consumption, which continued for the seventh consecutive year, the consumption of counterfeit cigarettes continued to grow, reaching 7.6 billion, a 38.3 percent increase compared to 2018 and the highest level recorded to date.

“The continued decline of illicit tobacco trade in the EU is a positive development and reinforces the importance of supply chain control measures, strict enforcement, and collaboration in combating this issue,” said Alvise Giustiniani, vice president of Illicit Trade Prevention at PMI. “We must remain focused on these collective efforts, as there continue to be worrying trends like the increase of counterfeit cigarettes and the persisting problem of illicit whites. The first ever EU-wide tracking and tracing system that was introduced last year under the European Tobacco Products Directive is an important tool for law enforcement and one that we should continue to enhance through close collaboration and information-sharing to remain highly vigilant on emerging risks.”

Illicit trade undermines efforts to reduce smoking prevalence and makes unregulated tobacco products easily accessible. For PMI to deliver a smoke-free future and enable millions of people who would otherwise continue to smoke to switch to better alternatives to cigarettes, it’s essential to eliminate illicit tobacco trade wherever it exists.

Interviews with law enforcement conducted by KPMG as part of the study indicate that the manufacture of illicit whites and counterfeit cigarettes in illegal factories located in the EU is increasing. Insights from law enforcement also refer to emerging organized crime groups that specialize in the smuggling and sale of illicit raw tobacco.

Other report findings reveal that:

- Counterfeit cigarettes represent 19.5 percent of total illicit cigarette consumption. Compared to 2018, the biggest increases in counterfeit consumption occurred in the U.K. (by 137 percent, to 2.1 billion cigarettes) and France (by 82 percent, to 0.84 billion cigarettes).

- Illicit whites continue to be a major element of illicit cigarette consumption, representing 35.6 percent of illicit consumption in the EU, or 13.8 billion cigarettes, up from 29.8 percent in 2018.

- For the first time since the research began in 2006, counterfeit cigarettes and illicit whites represent more than 50 percent of total illicit cigarette consumption in the EU.

- The countries with the largest volumes of illicit cigarette consumption in the EU were France, with 7.2 billion illicit cigarettes, and the U.K., with 5.5 billion illicit cigarettes.

- The highest shares of illicit cigarette consumption were found in Greece (22.4 percent), Lithuania (17.7 percent), and Ireland (17.5 percent). Compared to 2018, both Greece and Ireland saw a declining trend in illicit cigarette consumption, while Lithuania marked a slight increase.

- Illicit flows from identifiable markets outside the EU, such as Ukraine and Belarus, continued to decline. However, illicit products reportedly originated from within the EU—and destined to another EU country—increased in 2019.

PMI invests significantly in supply chain controls through preventive and protective measures, implements track-and-trace solutions worldwide in line with strict regulatory requirements, and applies comprehensive due diligence of customers and suppliers. The company supports regulations such as the FCTC Protocol to Eliminate Illicit Trade in Tobacco Products and the tracking and tracing provisions under the EU Tobacco Products Directive. Furthermore, PMI works with private and public actors alike to help advance the global anti-illicit trade efforts, including through PMI IMPACT, a global initiative supporting third-party projects against illegal trade and related crimes.

For more information about PMI’s illicit trade prevention efforts, visit StopIllegal.com .

About KPMG’s Report

A detailed overview of results and methodology is available here .

Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the United States. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables authorized by the U.S. Food and Drug Administration to Altria Group, Inc. for sale in the United States under license. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free IQOS product portfolio includes heat-not-burn and nicotine-containing vapor products. As of March 31, 2020, PMI estimates that approximately 10.6 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, available for sale in 53 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com .

# # #

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Canva Launches Creative Operating System30.10.2025 18:00:00 CET | Press release

Next era of Canva combines a supercharged Visual Suite, world-first design AI, and powerful tools to grow your brand Canva Design Model: World-first AI model that understands complexities and ingredients of design. AI Where You Work: Bring your imagination to life in every part of the design process, plus, a new design assistant. Video 2.0: A reimagined video editor makes professional and engaging content effortless. Canva Grow: Powerful marketing engine to ideate, create, distribute, and refine engaging ads to scale your brand. All-New Affinity: All-in-one app built by pro designers for pro designers, now forever free. Forms: Design interactive forms that can be added to any design for everything from RSVP forms to contact pages. Email Design: Design engaging emails with Canva’s drag-and-drop editor, then export to your platform of choice. Canva Code in Sheets: Seamlessly link interactive widgets with Canva Sheets to bring data to life in real time. Canva, the world’s only all-in-one

Svante Celebrates 18 Years of Carbon Management Innovation with Historic Milestones in 202530.10.2025 17:25:00 CET | Press release

Svante Technologies Inc. (Svante), a global leader in carbon capture and removal solutions, proudly marks its 18th anniversary this month, celebrating nearly two decades of pioneering industrial carbon management technology. This year has been one of the most transformative in Svante’s history, defined by bold innovation, strategic partnerships, and the commissioning of the world’s first commercial manufacturing facility for solid sorbent-based carbon capture and removal filters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030974500/en/ Founded in 2007 with a vision to revolutionize how the world manages carbon dioxide emissions, Svante has grown into a cornerstone of the global carbon management industry. In 2025, that vision took a monumental leap forward with the launch of the Redwood Facility in Burnaby, BC — a 141,000-square-foot Centre of Excellence for Carbon Capture and Removal. This first-of-its-kind manufactu

Ireland Unveils Seven New Halloween Experiences30.10.2025 15:00:00 CET | Press release

More celebrations than ever across the island of Ireland – the true Home of Halloween With seven brand-new Halloween hubs or experiences launching across the island this month, Ireland has truly become the ultimate destination to celebrate Halloween in 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022209535/en/ Derry Halloween Festival, County Derry~Londonderry Ireland’s Halloween Season Rooted in the ancient Celtic festival of Samhain, Halloween originated in Ireland more than 2,000 years ago and, this year, the island of Ireland is expanding its celebration like never before. With over 340 events planned across the island to celebrate this year, Halloween in Ireland is fast becoming a bucket-list travel experience. Seven new Halloween hubs join existing flagship events across the island of Ireland including the Púca Festival in County Meath and Derry Halloween in Derry-Londonderry which together welcomed over 169

Staloral® Birch Phase III Study Successfully Meets Primary Endpoint, Demonstrating Efficacy in Children and Adolescents30.10.2025 14:56:00 CET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, announced today that its Phase IIIb clinical study (YOBI, YOung patients and BIrch allergy), designed to confirm the safety and efficacy of Staloral® Birch in children and adolescents with birch pollen-induced allergic rhino-conjunctivitis (ARC), with or without asthma, has successfully achieved its primary endpoint. The trial enrolled 553 children aged 5 -17 years with moderate to severe birch pollen-induced ARC, with or without asthma, across 64 sites in 12 European countries and assessed the efficacy and safety of Staloral® birch 300IR daily maintenance dose administered pre-and co-seasonally over two consecutive birch pollen seasons. The YOBI study successfully met its primary endpoint, demonstrating the efficacy of Staloral® Birch in a paediatric population (5-17) with a 41% improvement in the ARC total combined score during the second pollen season compared to placebo. These results were highly statistically significant

Debiopharm Forges AI-powered Alliance With NetTargets to Pioneer Dual-payload ADCs Against Drug-resistant Cancers30.10.2025 14:00:00 CET | Press release

An Alliance to Combat Resistance: Debiopharm and NetTargets will collaborate to develop next-generation, dual-payload Antibody-Drug Conjugates (ADCs) designed to overcome acquired resistance mechanisms in difficult-to-treat cancers. AI-Powered Precision: The collaboration combines NetTargets' proprietary AI discovery platform—to identify synergistic drug pairings—with Debiopharm’s MLINK Duo technology for coordinated delivery of two distinct warheads on a single ADC. Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company dedicated to developing innovative therapies that respond to high unmet medical needs, today announced a strategic research collaboration with NetTargets (www.net-targets.com), a South Korean biotech company specializing in AI-enhanced systems biology for drug discovery, to rationally design and advance the discovery of novel, synergistic drug combinations for Debiopharm’s next-generation Antibody-Drug Conjugates (ADCs). This allianc

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye